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The failure to eradicate most cancers and in particular melanoma may be as fundamental
as a misidentification of the target. The identification of cancer stem/initiating cells within
the tumour population with a crucial role for tumour formation may open new pharmaco-
logical perspectives. Our data show three main novelties for humanmelanoma: firstly, mel-
anoma biopsy contains a subset of cells expressing CD133 (CD133+) and the latter is able to
develop a Mart-1 positive tumour in NOD-SCID mice. Secondly, the WM115, a human mel-
anoma cell line, has been found to express both CD133 and ABCG2 markers. This cell line
grows as floating spheroids, expresses typical progenitors and mature neuronal/oligoden-
drocyte markers and is able to transdifferentiate into astrocytes or mesenchymal lineages
under specific growth conditions. As in xenografts generated with CD133+ biopsy mela-
noma cells, those produced by the cell line displayed lower levels of CD133 and ABCG2.
Thirdly, the WM115 cells express the most important angiogenic and lymphoangiogenic
factors such as notch 4, prox1 and podoplanin which can cooperate in the development
of the tumourigenic capability of melanoma in vivo.
Therefore, in this study, we demonstrate the presence of stem/initiating subsets in mel-
anoma both in biopsy and in an established melanoma cell line grown in vitro and in xeno-
grafts. Interestingly, considering that melanoma gives metastasis primarily through
lymphatic vessels, herein, we demonstrated that a melanoma cell line expresses typical
lymphoangiogenic factors.
 2007 Elsevier Ltd. All rights reserved.er Ltd. All rights reserved.
fax: +39 2 50314932.
(C.A.M. La Porta).
contributions to the paper.
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The failure to eradicate most cancers may be as fundamental
as a misidentification of the target. Our current therapies suc-
ceed at eliminating bulky disease and rapidly proliferating
cells missing the tumour reservoir that is the source of dis-
ease recurrence and metastasis. For the last 30 years the idea
that cancer may originate from immature/stem cells under-
going genetic mutations has been postulated.1 The idea that
stem cells could be the origin of cancer cells was proposed
on the basis of their practically unlimited capacity to prolifer-
ate and their self-renewal property.2 Thus, if cancer arises
from a series of genetic mutations, stem cells may have more
opportunity to accumulate mutations because of their long
life-span. Cancer stem cells (CSCs) may represent only a
minority of the cells within the tumour, however, they could
be crucial for tumour formation. The involvement of cells dis-
playing a stem cell phenotype in cancer formation and pro-
gression has been confirmed in acute myeloid leukaemia3,4
and breast cancer.5 More recently, a number of papers
strongly support the idea that CSCs could be the basis for
the origin of human brain tumours6,7 and prostate cancer.8
From the pharmacological perspective, the tumour stem/
initiating cell hypothesis provides several new insights into
strategies for cancer treatment. In particular, cancer stem/ini-
tiating cells seem to retain the essential property of self-pro-
tection through the activity of multiple drug resistance
transporters. Therefore, different malignancies may appear
to be heterogeneous with respect to drug responsiveness. In
fact, a cancer can respond to therapy initially but it may ac-
quire drug resistance during the course of treatment. Other
cancers appear intrinsically resistant. In this context, the can-
cer stem cell hypothesis considers that these cells have in-
nate drug resistance by virtue of their capacity to remain
quiescent.
Malignant melanoma is increasing in incidence in the US,
Europe and Australia.9–11 Surgery remains the cornerstone of
treatment for patients with loco-regional disease. However,
while a few patients with advanced disease may be cured
by surgery, the majority of patients die of their disease.12 In
fact, cutaneous melanoma is among the most aggressive
types of human cancer and, if untreated, virtually every mel-
anoma has the potential to metastasise. Melanoma is defined
as a neuroectodermal malignant tumour deriving from the
transformation and the proliferation of melanocytes which,
normally, reside in the basal cell layer of the epidermis. Re-
cently, the gene expression analyses of cutaneous and uveal
melanoma cells revealed that more aggressive tumour cells
express genes associated with multiple phenotypes, includ-
ing genes normally associated with neuronal, vascular and
skeletal muscle and other precursor cell types. These findings
seem to indicate that the more aggressive melanoma may
contain deregulated cells with undifferentiated/stem cell-like
phenotype.13–15 Consistent with this hypothesis is the recent
observation that well established metastatic melanoma cell
lines have been shown to exhibit multiple morphological,
phenotypic, functional forms.16
In the present work we assess if melanoma tumours con-
tain a subset of cells expressing genes, markers and stem/ini-
tiating cells-like properties. Basing the study on differentreports that suggested CD133 as a marker of cancer/initiating
cells in human glioblastoma,6,7,17,18 we first wanted to inves-
tigate the expression of CD133 marker in fresh tumour biop-
sies and in a continuous melanoma cell line (WM115) and
then to characterise the CD133+ melanoma cell subset for
tumourigenic potential, angiogenic and lymphoangiogenic
properties. Secondly, since ABCG2, the second member of
the G family of ABC transports, expression correlates with
cancer cells with high tumourigenic potential,19,20 we investi-
gated whether melanoma cells express ABCG2 both in vitro
and in tumour xenografts.
Taken together, our findings demonstrate that, as in glio-
blastoma, humanmelanomas contain in vivo cancer stem/ini-
tiating cells with enhanced tumourigenic potential and that
these cells can be identified by the expression of CD133,
ABCG-2, angiogenic (notch 4) and lymphoangiogenic (prox-
1) markers.
2. Materials and methods
2.1. Reagents
Oil Red and isopropanol were obtained from Sigma-Aldrich
(St. Louis, USA).
2.2. Isolation of single melanoma cells from melanoma
biopsy
Melanoma biopsy (seven) was obtained from the National Ital-
ian Institute of Tumour of Milan, Italy, after received approval
from the appropriate local Institutional Review Board. Mela-
nomametastatic specimens (around 1 g) were obtained during
surgical procedure. After several washes, tumour fragments
were finely minced with scissors and then incubated for 2 h
at 37 C in DMEM medium (Gibco, Grand Island, New York,
USA) containing 0.2% of collagenase type I (Gibco) and 0.2% bo-
vine serum albumine (BSA) (SIGMA). The tumour cell suspen-
sions were washed in DMEM + 10% fetal bovine serum (FBS)
(Gibco) and passed through a 100 lm pore size filter to remove
undigested tumour tissue macroaggregates. After centrifuga-
tion at 1000 g, the pellet was resuspended in DMEM/F12 (Euro-
clone, Leeds, UK)mediumoptimised for growth of neural stem
cells (NSC),2 containing 20 ng/ml EGF (Sigma), 20 ng/ml bFGF
(BoehringerMannaheim Indianapolis IN, USA) 2 mmol/L gluta-
mine, 0.6% glucose, 9.26 lg/ml putrescine, 6.3 ng/ml progester-
one, 5.3 ng/ml sodium selenite, 25 lg/ml insulin, 100 lg/ml
grade II transferrin sodiumsalt and 0.6%BSA (all reagentswere
purchased from Sigma, St. Louis, MO, USA). After counting,
cells were immediately used for further analysis.
2.3. Isolation of CD133 positive cells biopsy
Single melanoma cells were isolated from biopsy as described
above as well as CD133+ cells using CD133 Cell Isolation Kit
(Miltenyi Biotec SRL, Italy). An aliquot of cells were evaluated
for purity by flow cytometry. Purities ranged from 70–80% for
CD133+ (Mart-1+) and 95–98% for CD133 (Mart-1+) cells and
they were injected in NOD-SCID mice as described below. Fur-
thermore, these cells were Mart-1 positive as described in the
immunohistochemistry section.
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Human primary melanoma WM115 (ATCC CRL 1675) was cul-
tured as in previous work.21 Since the genetic stability of cell
lines under long-term culture conditions is not well defined,
we performed the DNA fingerprinting assay on eight highly
polymorphic microsatellite STR loci plus gender determina-
tion which has been found to be the best tool to screen the
uniqueness of DNA profiles in a fingerprint database.22 The
WM115 Short-tandem-repeat (STR) profiling (DNA finger-
printing) was performed using PowerPlex 16 System (Prome-
ga) on following STR loci: Amelogenin (X); CSF1PO (12);
D13S317 (12,13); D16S539 (11,12); D5S818 (13); D7S820 (8);
THO1 (7,9); TPOX (8,11); vWA (15,1). The results in brackets
showed the perfect match with ATCC profile. Human mela-
noma cell lines, IGR-37 (metastasis), IGR-39 (primary) were
grown in DMEM medium supplemented with 15% foetal bo-Table 1 – Primers, annealing conditions and length of PCR pro
Gene Primer sense
Notch 1 5 0-GGTCAATGCGAGTGGC 5 0-
Notch 2 5 0-CGTTTAGTCAGGAATATGCGG 5 0-
Notch 3 5 0- GCTTCTCAGGTCCTCGCTGT 5 0-
Notch 4 5 0-TCTGGGGCCCGGGCTGAAGAAAG 5 0-
Jagged 1 5 0-ACCTTTAACAAGGAGATGATG 5 0-
Jagged 2 5 0-CTCCATCGATGGACTTCAGC 5 0-
DLL 1 5 0-AACAAGAAAACCCCTCTCCTCAC 5 0-
DLL 3 5 0-GCGTGGAAAGGGATGAATGC 5 0-
DLL 4 5 0-CTGGGTGCGTCTCTTGCT 5 0-
Sox 18 5 0-ACCCTTCCTGGGCTTCTG 5 0-
endogline 5 0-AGCAGGAGAGACTGAGCAGC 5 0-
Semaphorine 3A 5 0-CCCTGGAAGTCATTGACACAG 5 0-
Semaphorine 3F 5 0-GGCAGCCTAGCCCTTGTC 5 0-
podoplanin 5 0-CCAGGAACCAGCGAAGACC 5 0-
PROX-1 5 0-TTCAGATGGAGAAGTACGCA 5 0-
VEGFR3 5 0-AGCCATTCATCAACAAGCCT 5 0-
CD133 5 0-TACCAAGGACAAGGCGTTCAC 5 0-
adipsin 5 0-GGTCACCCAAGCAACAAAGT 5 0-
ABCG2 5 0-CCAGTTCCATGGCACTGGCCATA 5 0-
ABCB1 5 0-GCAAAGCTGGAGAGATCCTCACCA 5 0-
GAPDH 5 0- TCTAGACGGCAGGTCAGGTCCACC 5 0-
VEGF 5 0-GGCCAGCACATAGGAGAG 5 0-
Nested primers for VEGF 5 0-CAGCACATAGGAGAG 5 0-
Flt-1 5 0-TTTTACCGAATGCCACCTC 5 0G
KDR 5 0-GAACCAAATTATCTCCATCTT 5 0-
Nested primers for KDR 5 0-TGTGGCATCTGAAGGCTCAA 5 0-
Ang-1 5 0-ACCGAGCCTATTCACAGTAT 5 0-
Nested primers for Ang-1 5 0-CGAGCCTATTCACAGTAT 5 0-
Ang-2 5 0-TTCTAAACATCCCAGTCCAC 5 0-
Nested primers for Ang-2 5 0-TCTAAACATCCCAGTCCAC 5 0-
Tie-2 5 0-GTCCCGAGGTCAAGAGGTG 5 0-
CD31 5 0-AGTGGTTATCATCGGAGTG 5 0-
Nested primers for CD31 5 0-AGTGGTTATCATCGGAGTG 5 0-
Tie-1 5 0-GCCATGATCAAGAAGGACGG 5 0-
Neuropilin 1 5 0-ATGGAGAGGGGGCTGCCG 5 0-
Neuropilin 2 5 0-ATGGATATGTTTCCTCTCACC 5 0-
E-Cadherin 5 0-GCCAAGCAGCAGTACATTCTACACG 5 0-
N-Cadherin 5 0-GTGCCATTAGCCAAGGGAATCAG 5 0-
P-Cadherin 5 0-GACCAACGAGGCCCCTTTTGTGCG 5 0-
Eph-A2 5 0-CTCACACACCCGTATGGCAA 5 0-vine serum and A375 (metastasis) in DMEM and 10% foetal
bovine serum.2.5. Animal experiments
Five-week-old NOD-SCID mice were purchased from Charles
River Laboratories. 5 · 105 WM115 cells were injected subcuta-
neously and after 60 days the tumour was isolated, treated
with 0.2% of collagenase type I (Gibco) and 0.2% bovine serum
albumine (BSA) (SIGMA) for 30 min shacking at 37 C. After a
brief centrifugation, the cells were prepared for FACS analysis
while they were seeded for Western blot, RT-PCR or immuno-
fluorescence analysis overnight (time zero). Biopsy sorted po-
sitive or negative CD133 cells (3.5 · 105) were injected
subcutaneously in 200 ll of phosphate buffered saline (PBS)
and after 40 days the mice (four animals) were sacrificed,ducts
Primer reverse Fragment
size bp
Annealing
temperature
GGCAGCAAGGCTACTGTG 153 50 C
GGACACATTTATGTACCCAGAG 146 58 C
GGCACAGTGACAGGTGAAGG 124 60 C
ACGCCGGATGAGCTGGAGGACGAGA 393 66 C
CTCAATTCACTGCAAATGTGC 62 56 C
CACATTCCGTTTGATAGTGG 131 56 C
CTCTGCGGAACTCCAAGAATCTA 318 63 C
TTTCGCTGGCAGGGTTAGGC 465 58 C
AAGGGCCTAGACCAGAGAGC 122 56 C
AAAAGGAGCAGGTGCTTCAA 153 55 C
CAAGTGGTCTGTCTCCTGGG 236 60 C
GGTATGTCCTGGCCTTTGCCG 230 60 C
TGGTTAGGCAGGCTCTGTTT 210 55 C
GCGTGGACTGTGCTTTCTGA 119 57 C
GGACTGCTACTCTTCATACA 360 53 C
GGCAACAGCTGGATGTCATA 298 53 C
CAGTCGTGGTTTGGCGTTGTA 470 59 C
CCTCCTGCGTTCAAGTCATC 272 56 C
CAGGGCCACATGATTCTTCCACA 347 60 C
CAACATTTTCATTTCAACAACTCCTGC 305 60 C
CCACCCATGGCAAATTCCATGGCA 598 58 C
TGCAGGAACATTTACACG 157 50 C
TGCAGGAACATTTACACG 154 50 C
CGTGCTAGCTGGATGTCTT 159 58 C
GCACTCCAATCTCTATCAGC 180 58 C
GCACTCCAATCTCTATCAGC 125 58 C
CAAGCATCAAACCACCATCCT 180 55 C
CAAGCATCAAACCACCATCCT 178 55 C
CCCGTCAGCACCGAGCACAC 132 50 C
CCCGTCAGCACCGAGCACAC 131 50 C
CAAGTCATCCCGCAGTAGG 177 60 C
TCATTTATTGGTTTCATT 222 50 C
CTGCTGGCCTGGACATTTC 110 50 C
GTTCTCTCCGACCAGCACAT 407 55 C
CAACATCAGGGAATCCATCCC 659 55C
CTGGAGATACTCCTTGTTGG 989 55 C
GCTGTTCTTCACGTGCTCAAAATC 341 68 C
GCGTTCCTGTTCCACTCATAGAG 369 68 C
GTGGTGGGGGGCTTCC TTGTCCA 356 68 C
GGCTCTCAGATGCCTCAAAC 736 60 C
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immunohistochemistry.
2.6. Cytofluorimetric analysis
Subconfluent cells were fixed in iced ethanol at 4 C. Cells
were stained with a monoclonal antibody anti CD133 PE-con-
jugated, clone 2 (Miltenyi Biotec S.r.l., Italy; this antibody does
not cross-react with mice) or anti-CD133, epitope 2 (CD133/2)
(Miltenyi Biotech) or anti-ABCG2-FITC conjugated (Chem-
icon). We have also carried out experiments fixing after stain-
ing and we obtained the same results. Data were acquired
with a FACSscanplus (Becton-Dickinson) equipped with an ar-
gon-ion laser (excitation wavelength 488 nm, laser power
200 mW) (500–600 cells/s). Typically 30,000 cells were analysed
per sample. DNA deconvolutions were carried out using the
software program CELLQUEST (Becton-Dickinson). The exper-
iments were repeated at least four times. For CD133/2, non
specific staining was evaluated using a monoclonal antibody
for IgG1 and IgG2a (Simultest control, Becton Dickinson, CA).
2.7. Differentiation assays of melanoma cells
Melanoma cells were induced to differentiate towards differ-
ent mesenchimal lineages such as adipogenic according to
Barbero et al.10 After differentiation, cells were incubated in
Oil Red O solution (0.6% in 60% isopronanol) for 25 min and
counterstained with haematoxylin for 10 s. The extent of adi-Fig. 1 – Expression of CD133 in human melanoma biopsies (sev
NOD-SCID mice. (A) A representative flow cytometry analysis. M
containing 0.2% of collagenase type I and single cells were fixed
The dot-plot shows the percentage of CD133+ cells less than 1%
(CD133 Cell Isolation Kit) from melanoma biopsies. One hundre
NOD-SCID mice (four). Detectable tumour appeared 40 days later
Immunohistochemistry of Mart1 was performed to assess the m
The injection of CD133– cells did not give a detectable tumour.pogenic differentiation was determined by counting the num-
ber of positively stained cells in 24 independent microscope
fields (total area analysed in each experimental
group = 40 mm2). The results are reported by the mean ±
standard differentiation (SD). Part of differentiated cells was
used for the analysis of adipsin by RT-PCR.
2.8. Immunofluorescence and immunohistochemistry
analysis
For immunofluorescence analysis, the cells were fixed in 4%
paraformaldeide rinsed with phosphate-buffered saline (PBS)
and incubated for 90 min at 37 C in PBS containing 10% nor-
mal goat serum, 0.3% Triton-X100 (omitted when antibodies
against membrane-bound antigens were used) and appropri-
ate primary antibodies for 20 min: anti- btubulin type III
(Tuj1; 1:500; Babco), anti-microtubule-associated-protein 2
(MAP2) (1:300, Immunological Science), anti-nestin (1:200,
Chemicon), anti-PSA-NCAM (1:500, Produits Valbiotec), anti-
A2B5 (1:1000, Chemicon), anti-O4 (1:100, Chemicon), anti-
GFAP (1:300; Dako, Carpinteria, CA), anti-GalC (1:100, Chem-
icon), anti-Ki67 (1:1000, Novocastra). For anti-CD133 (1:100,
Abcam; this antibody cross-reacts with mice and humans),
an a 2h incubation at 4 Cwas carried out. Then, the cells were
incubated with the suitable anti-mouse immunoglobulin G
(IgG) (1:300 Cy3; Jackson Immunoresearch) for 45 min. Regard-
ing CD133, the cellswere incubatedwith goat anti-rabbit Alexa
488 (1:700; Molecular Probes), and the nuclei were stainedwithen) and tumour-initiating capability of CD133+ cells in
elanoma specimens were incubated for 2 h in medium
in iced ethanol and stained with anti CD133 PE-conjugated.
. (B) CD133+ cells were obtained by beads sorting
d thousand cells were injected subcutaneously into
. Photography shows a representative size tumour obtained.
elanocytic origin of the tumour growth in NOD-SCID mice.
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suitable anti-immunoglobulin G: anti-mouse immunoglobulin
G (IgG) (1:300, Cy3; Jackson Immunoresearch) for 45 min. For
rodhamine uptake,WM115 cellswere grown in 9.6 cm2 culture
dishes in DMEM containing 2% FBS. Rhodamine 123 (0.1 lg/ml,
Sigma Aldrich) was added directly to each culture dish, and
the cells were incubated for 20 min at 37 C. After rhodamine
staining, the cells were fixed in 4% paraformaldehyde for
20 min at 4 C. The nuclei were stained with DAPI.
For immunohistochemistry, the cells were fixed in 95%
ethanol and the antigens were unmasked by means of heat-
ing in a microwave oven at 750 w in 10 nmol/L citric acid buf-
fer (pH 6.0) for 5 min. The cells were incubated with the
specific antibody Mart-1 (DAKO, 1:40), VEGFR-3 (kind gift of
Alitalo, 1:100), LYVE-1 (Alexis, 1:100), prox-1 (Alexis, 1:100) or
D2-40 (Signet, 1:160), overnight at 4 C. Then, the cells were
treated with biotinylated secondary antibodies and the avi-
din-biotin peroxidase complex kit (Dako Cytomation A/S,
Glostrup, Denmark).
2.9. Western blot
Fifty micrograms of proteins were run in 10% SDS-PAGE and
transferred on PVDF sheet.23 The blots were incubated for 1–Fig. 2 – Expression of CD133 in WM115 human melanoma cell
carried out. (A) Total RNA was extracted from WM115 cells usin
contamination, samples were treated with RNase-free DNase I a
positive control, human neural stem cells were used according
and then sequenced. GAPDH was used as housekeeping gene. (B
Cells were fixed in iced ethanol stained with anti CD133 PE-con
The gray line shows the autoflorescence of the cells. (C) Cells w
stained with anti-CD133 2h (1:100, Abcam). The nuclei were sta
expression in WM115 cells. The latter were stained with anti-C
conjugated (Chemicon). No specific staining was evaluated usin
control).2 h in blocking solution (5% skimmed milk in Tris-buffer),
then for 1 h with the following primary antibodies: anti-
CD133 (2 lg/ml) (Abcam); anti-podoplanin (2 lg/ml) (Relia-
Tech, Braunschwaig, Germany); beta-actin, (1:5000) (Sigma).
Next the sheet was incubated for 1 h with HRP-conjugated
secondary antibodies (Amersham Pharmacia Biotech) against
mouse or rabbit immunoglobulins. The bands were visualised
using the ECL-Plus detection system (Amersham Pharmacia
Biotech).
2.10. RT-PCR analysis
Total cellular RNA was extracted from human cell lines
using the RNeasy Mini Kit (Qiagen) and complementary
DNA (cDNA) was synthesised using 3–5 lg of total RNA
(eAMV-RT, Sigma); 2 ll of cDNA was used for PCR analysis
according to Table 1 and for nested PCR, 2 ll of the first
product was amplified using the primers shown (Table 1).
During RNA preparation, to exclude potential genomic
DNA contamination, samples were first treated with
RNase-free DNase I and then analysed using RT-PCR.
GAPDH was used as housekeeping gene. Finally, to check
the specificity of the amplification, all the bands were puri-
fied and sequenced.line. All the panels show a representative result out of four
g the RNeasy Mini Kit. To exclude potential genomic DNA
nd then complementary DNA (cDNA) was synthesised. As
to Cavazzini et al.36 (lane 1). A band of 470 bp was amplified
) Flow cytometry of CD133 expression in WM115 and IGR 39.
jugated (Mylteni). WM115 cells express CD133 (green line).
ere fixed with 4% paraformaldehyde for 20 min and then
ined with DAPI. (D) Flow cytometry of CD133 and ABCG2
D133-PE (Mylteni) conjugated and anti-ABCG2-FITC
g a monoclonal antibody for IgG1 and IgG2a (negative
Fig. 3 – The stem/initiating phenotype of WM115 cells. (A) WM115 cells grown in standard medium as spheroids under non
adherent plate (Nunc). Herein is shown a typical example. (B) Immunofluorescence of beta-tubulin type III, A2B5 and GalC in
WM115 cells. The cells were fixed with 4% paraformaldehyde and incubated with anti-tubulin type III (Tuj1; 1:500), anti A2B5
(1:1000) or anti-GalC (1:100) overnight at 4 C. Then the cells were incubated with the suitable anti-mouse immunoglobulin
(IgG) (1:300) for 45 min. DAPI was used to stain nuclei. Double staining between MAP2 (red, 1:300, Immunological Science) and
CD133 (green; 1:100 Abcam) overnight showed that all the cells are positive for both markers (beta-tubulin gave the same
results, not shown). (C). The cells were grown in DMEM/F12 medium in the absence of EGF for 72 h and then for an additional
6 days in medium without EGF and FGF-2 but with 2% foetal bovine serum (FBS). Then, the cells were fixed with 4%
paraformaldehyde and then incubated with anti-GFAP (1:300) overnight at 4 C. Nuclei are stained with DAPI.
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3.1. Fresh CD133+ cells isolated from melanoma
specimens demonstrate tumour-initiating property in vivo
In order to investigate the possible presence of a stem/initiat-
ing cell population in melanoma, we first analysed the
expression of CD133 in seven human melanoma specimens.
Briefly, fresh surgical biopsy was mechanically/enzymatically
disaggregated and the resulting single cells suspension was
analysed by FACS. As shown in Fig. 1 (panel A), we have found
less than 1% (0.5; 0.8; 0.3; 0.8; 0.2; 0.3; 0.2% for each biopsy,
respectively) of cells positive for CD133. In accordance with
the idea that cancer stem/initiating cells may represent only
a small percentage of the tumour cell population, we then
tested the tumourigenic capacity of CD133+ melanoma cells.
Thus, upon magnetic beads selection, the sorted CD133+ or
CD133 cells were injected subcutaneously into 5-week old
NOD-SCID mice. After 40–50 days, the mice injected with
CD133+ cells developed a detectable tumour (Fig. 1, panel B,
0.2 g), whereas mice injected with CD133– melanoma cells
did not develop a tumour even 4 months after injection. Thisresult was obtained in all the metastatic melanoma speci-
mens processed. To confirm that tumours originating in mice
were melanomas, the animals were sacrificed and histology
of the tumour was performed. As shown in Fig. 1 (panel B),
the expression of Mart-1, a typical melanocyte marker, was
detected before and after the injection in NOD-SCID mice.
3.2. WM115 human melanoma cell line contains cells
with cancer stem/initiating-like properties and expresses
markers of stem/progenitor cells
Important in vivo results seem to demonstrate that melanoma
behaves like other neuroectodermal tumours6,7 and only a
minor fraction of CD133+ tumour cells was able to recapitu-
late the original tumour. Therefore, to bypass the problem
that there is a low number of cells CD133+ in biopsy and that
long-time in culture can alter the expression of pivotal cellu-
lar markers and, more importantly, can alter their biological
behaviour, we used a well established, tumourigenic and ge-
netic stable melanoma cell line, WM115, extensively studied
by our group21 for further studies on stem cell properties of
melanoma. Since the genetic stability of cell line under
Fig. 4 – Differentiation of WM115 cells into mesenchymal lineage. (A) Subconfluent cells were treated with adipogenic
induction medium (see Section 2) for 72 h and then with adipogenic maintenance medium (see Section 2) for 24 h. WM115
cells incorporate Oil Red after differentiation (see arrows). The extent of adipogenic differentiation was determined by
counting the number of positively Oil Red stained cells in 24 independent microscope fields. In the histograms are reported
the mean ± SD. *p < 0.001 versus undifferentiated WM115 cells. (B) Level of expression of adipsin by RT-PCR. Total RNA was
extracted from WM115 cells using the RNeasy Mini Kit. To exclude potential genomic DNA contamination, samples were
treated with RNase-free DNase I and then complementary DNA (cDNA) was synthesised. A band of 272 bp was amplified and
then sequenced. GAPDH was used as housekeeping gene. The ratio between the densitometric values of adipsin of
undifferentiated and differentiated cells with respect to housekeeping gene show an increase in the level of expression of
adipsin after differentiation (1.5-fold).
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formed the DNA fingerprinting assay on eight highly
polymorphic microsatellite STR loci plus gender determina-
tion demonstrating a perfect match with ATCC profile (see
Section 2). We first investigated for the presence of CD133.
As shown in Fig. 2, we found that practically all WM115 cells
expressed CD133 by means of FACS analysis, immunofluores-
cence and RT-PCR. We have also analysed other melanoma
cell lines (A375, IGR 32 and IGR39), all positive for CD133
(Fig. 2 shows IGR 39). CD133+ cells were also positive for
ABCG2 (Fig. 2, 3%). However, we have chosen to use as model,
WM115 cells, since we have previously characterised such a
cell line and they are tumourigenic in vivo.21 The stem/pro-
genitor phenotype of this cell line was confirmed by its capac-
ity to survive and grow as floating spheroids when cultured in
a serum free medium or in a non-adherent plate (Fig. 3, panel
C) and by the analysis of neurogenic markers. Basically,
WM115 cells positive for CD133 expressed markers of neural
(b-tubulin type III and MAP2), but not of their precursors (nes-
tin and polysialic neural cell adhesion molecule) whereas
they expressed markers of oligodendrocytes and of their pre-
cursors (GalC and A2B5) (Fig. 3). In contrast, GFAP (presumedto be expressed by differentiated astrocytes) and antigen O4
(expressed in pre-oligodendrocytes) were undetectable
(immunofluorescence, data not shown). However, when the
cells were maintained in a differentiating medium like that
for neural stem cells,24 they started expressing GFAP, without
any significant morphological differences (Fig. 3, panel B).
Furthermore, since melanocyte are derived from the neu-
ral crest during embryonic development and the transient
neural crest consists of pluripotent stem cells that give rise
to a wide array of lineages including cephalic mesenchyme,
we have investigated whether WM115 can differentiate into
mesenchymal lineages such as adipogenic. The extent of adi-
pogenic differentiation was determined by counting the num-
ber of positive Oil Red stained cells. WM115 did not stain for
Oil Red, however, after culture conditions that sustained adi-
pogenic differentiation, more than 30% of the cells acquired
positivity for Oil Red (Fig. 4, panel A). These cells are also neg-
ative for CD133 (not shown). RT-PCR of adipsin, a typical adi-
pogenic marker, was carried out to confirm adipogenic
differentiation. As shown in Fig. 4 (panel B) a substantial
increment (1.5-fold versus control) of adipsin expression
was observed.
Table 2 – Summary of angiogenic/vasculogenic factors as
well as adhesion and stem cell markers expressed by
WM115 cells
Gene Expressed (+)
VEGF +
FLt-1 
Flk-1 +
Nrp-1 +
Nrp-2 +
Ang-1 +
Ang-2 +
Tie-1 
Tie-2 +
Ephrine A2 +
CD31 +
Endogline +
Notch 4 +
JAG1 
JAG2 
DLL1 
DLL3 
DLL4 
Sox1 8 
Semaphorine 3A +
Semaphorine 3F 
E-cadherin 
N-cadherin +
P-cadherin 
ABCG2 +
ABCB1 
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lymphoangiogenic markers
An essential feature of cancer stem/initiating cells is their
capacity to express vasculogenic-angiogenic properties in or-
der to establish a tumour in vivo. To this end we analysed the
expression of the pivotal factors involved in vasculogenesis/
angiogenesis by RT-PCR. In Table 2 are reported all the factors
expressed by WM115 cells. Interestingly WM115 cells express
stem cell-like factors such as notch 4 and many other factors
linked to vasculogenesis/angiogenesis. Since melanoma uses
lymphatic vessels to metastasise, we have analysed whether
WM115 cells express typical markers of lymphatic endothe-
lium such as VEGFR-3, LYVE-1, prox1 and podoplanin. As
shown in Fig. 5, VEGF-R3, LYVE1, prox1 and podoplanin were
expressed in WM115 cells where no signal has been detected
for D2-40. The magnification for D2-40 (20 and 100X) was cho-
sen to emphasise that allWM115 cells do not express thismar-
ker. In addition, since podoplanin showed faint levels by
immunohistochemistry, Western blot analysis was also car-
ried out (Fig. 5).
3.4. Expression of CD133 and ABCG2 in WM115 cells
grown in vivo in NOD-SCID mice
We wanted to investigate the levels of CD133 and ABCG2 in
tumour xenograft obtained by injecting WM115 cells in
NOD-SCID mice. In fact, cell lines maintained in vitro oftenFig. 5 – Expression of typical lymphoangiogenic markers. Immunohistochemistry of VEGF-R3, D2-40, prox1, podoplanin and
LYVE-1 in WM115 human melanoma cells fixed in 95% ethanol and processed with the standard avidin-biotin peroxidase
complex. DAB was used as chromogen. Due to the low level of expression of podoplanin by immunohistochemistry, Western
blot analysis was also carried out. 50 lg of protein was loaded on 10% SDS-PAGE and complex antigen-antibody was detected
with ECL system. WM115 cells express VEGFR-3, prox-1, podoplanin, LYVE-1 while D2-40 is undetectable. The magnification
for D240 (20 and 100X) was chosen in order to emphasise that all WM115 do not express this marker. Instead for other
lymphoangiogenic markers the magnification used (100X) allowed better visualisation of the presence of these markers
(VEGF-R3, prox-1, LYVE-1, podoplanin). The figure shows a representative experiment out of the four carried out.
Fig. 6 – Tumour xenografts of WM115 in NOD-SCID mice and expression of CD133 by flow cytometry, Western blot, RT-PCR
and immunofluorescence. 500,000 cells were injected subcutaneously into NOD-SCID mice and the tumours were analysed
after 60 days (five animals). (A) A representative flow cytometry analysis. Tumours were incubated for 2 h in medium
containing 0.2% of collagenase type I and single cells were fixed in iced ethanol and stained with anti CD133 PE-conjugated
(Myliteni) (red line). The same analysis was performed on WM115 cells grown in vitro (green line). (B) 50 lg of tumour
xenograft lysates (lane 1) or WM115 cells (lane 2) were loaded on 10% SDS-PAGE and the antigen-antibody complex was
detected with ECL system. Beta-actin was used as housekeeping gene. (C) Level of expression of CD133 by RT-PCR in WM115
cells (lane1), in tumour xenograft (lane 3) and in single cells isolated by tumour xenograft and maintained in vitro for 2–3
passages (lane 2). Total RNA was extracted from WM115 cells using the RNeasy Mini Kit. To exclude potential genomic DNA
contamination, samples were treated with RNase-free DNase I and then complementary DNA (cDNA) was synthesised. A
band of 470 bp was obtained and sequenced. GAPDH was used as housekeeping gene. (D) Immunofluorescence analysis of
CD133 in WM155 cells (in vitro) and in tumour xenograft. Single cells obtained as described above were immediately fixed
with 4% paraformaldehyde for 20 min and incubated with anti-CD133 (1:100, Abcam). The nuclei were stained with DAPI. All
together the data shows that in vivo the WM115 cells express lower levels of CD133 than in vitro.
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which they were derived. The injection of 5000 cells produced
a tumour of 350–380 mg in weight after 4 months while 5 · 105
cells gave a tumour of the same weight 2 months after. The
level of expression of CD133 was investigated by means of
FACS, RT-PCR, Western blot and immunofluorescence. Fig. 6
clearly shows a decreased expression of CD133 in tumor
xenograft. Interestingly, even ABCG2 level was lower in re-
spect to WM115 cells grown in vitro (Fig. 7, panel A). By con-
trast, WM115 cells did not express ABCB1 either in vitro or
in vivo (not shown). Accordingly, WM115 cells were negative
for rodhamine up-take while in tumour xenograft, 20% of po-
sitive cells were counted (Fig. 7, panel B).
In order to investigate whether the in vivo decrement of
both CD133 and ABCG2 expression was reversible under cul-
ture conditions, melanoma cells isolated from tumour xeno-
graft were cultured for 2–3 passages and then analysed for
the expression of these markers by RT-PCR. As shown in Figs.6 (panel C) and 7 (panel A), both CD133 and ABCG2 markers
were re-expressed.
3.5. Expression of CD20, CD133 and ABCG2 in spheroid
WM115 cells
A recent paper has shown that WM115 cells propagated as
non-adherent spheres (melanoma spheroid cells) expressed
higher levels of CD20 in comparison to WM115 adherent cells.
Melanoma spheroid cells appeared to be more tumourigenic
when grafted into mice.25 Thus we have investigated by flow
cytometry the expression of CD133 and ABCG2 in adherent
and spheroid WM115 cells in comparison to CD20. According
to a previous paper, WM115 cells did not express CD20 when
grown as adherent cells in vitro, while the melanoma spher-
oids were enriched in such a factor (data not shown). Interest-
ing, the expression of CD133 and ABCG2 was significantly
lower in melanoma spheroids cells than in their adherent
Fig. 7 – Levels of expression of ABCG2 in WM115 cells and tumour xenograft. Panel A. RT-PCR of ABCG2 in WM115 cells (lane
1), in tumour xenograft (lane 3) and in single cells obtained by tumour xenograft and maintained in vitro for 2–3 passages
(lane 2). 500,000 WM115 cells were injected subcutaneously into NOD-SCID mice (five animals) and the tumours were
analysed after 60 days. Total RNA was extracted from WM115 cells using the RNeasy Mini Kit. To exclude potential genomic
DNA contamination, samples were treated with RNase-free DNase I and then complementary DNA (cDNA) was synthesised.
A band of 347 bp was obtained and sequenced. GAPDH was used as housekeeping gene. Panel B. Rhodamine uptake in
WM115 melanoma cells grown in vivo in NOD-SCID mice (arrows). 500,000 cells were injected subcutaneously into NOD-SCID
mice and the tumour was resected after 60 days. Single cells were obtained and incubated with 0.2% of collagenase type I and
maintained in growth medium for a night. Then the cells were incubated with rhodamine (0.1 lg/ml) for 20 min at 37 C and
than fixed with 4% paraformaldehyde for 20 min at 4 C. The nuclei were stained with DAPI.These data show lower levels of
ABCG2 and higher up-take of rhodamine in tumour xenograft with respect to WM115 cells maintained in vitro. Furthermore,
in vitro tumour cells isolated by xenograft re-started to express both CD133 and ABCG2 after few passages in vitro. Levels of
CD133 and ABCG2 in WM115 cells and in WM115 spheroids. Panel C. Flow cytometric analysis for CD133 expression on
spheroid or adherent cultures of WM115 cells. Fixed cells were incubated with anti-CD133 (epitope 2, CD133/2) (Shaded areas,
isotype-matched control; solid lines CD133). The figure shows a typical experiment out of three carried out. No specific
staining was evaluated using a monoclonal antibody for IgG1 and IgG2a. Panel D. Total RNA was extracted from WM115 cells
using the RNeasy Mini Kit. To exclude potential genomic DNA contamination, samples were treated with RNase-free DNase I
and then complementary DNA (cDNA) was synthesised. A band of 347 and 470 bp was obtained for ABCG2 and CD133,
respectively and sequenced. GAPDH was used as housekeeping gene.
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(data not shown).
4. Discussion
The hypothesis that a tumour may originate from the accu-
mulation of genetic alterations inside immature progenitor/
stem cells can be substantially summarised by three major
observations: i) striking phenotypic similarities between nor-
mal and CSCs, ii) similar self-renewal potential of stem cell
and cancer cells,26,27 iii) within the tumour mass only a rare
fraction of tumour cells are able to recapitulate the original
tumour.26,27 In haematological malignancies such as leukae-
mia,3–5 multiple myeloma,26 solid tumours such as breast
cancer,5 and more recently in brain tumours,6,7 rare cells were
isolatedwith a remarkable potential of self-renewal and these
cells alone were found to drive the formation of the original
tumours.
Herein we wanted to investigate whether human mela-
noma could contain tumour cell subsets that can be referredto as cancer stem/ initiating cells. To this end, we initially
analysed the presence of the marker CD133 in fresh human
melanoma specimens, because this marker has been found
to be expressed in other tumour originating cells.5–7
In agreement with the general thinking that cancer stem
cells may represent only a very minimal part of the total tu-
mour cell population, we found that CD133 was expressed
in a very small percentage of the total melanoma cell popula-
tion obtained from fresh metastatic specimens. All of the
biopsies analysed (nine) never expressed CD133 above 1% of
the total cells examined. Most significantly, only the CD133+
cells, but not their CD133– counterpart of fresh melanoma
cells, were able to re-form a melanoma tumour when trans-
planted in NOD-SCID mice, as confirmed by the histology of
the tumour xenograft and the expression of Mart-1, a typical
melocytic marker. If confirmed by a larger sample of mela-
noma biopsies, to our knowledge, this result may be relevant
in human melanoma tumour biology. Moreover, it is interest-
ing to note that, like glioblastoma, the tumourigenic potential
of melanoma seems to be retained only in cells expressing
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originate from a common ancestral progenitor. This hypothe-
sis could be sustained by the evidence that skin derived stem
cells can differentiate into neurogenic cell lineages.28
Whether other neuroectodermal derived tumours share sim-
ilar properties remains to be investigated. Since few cells
were CD133+ in melanoma biopsy, we analysed the expres-
sion of CD133 in a well established humanmelanoma cell line
named WM115 because of its strong tumourigenic potential
and their further previous characterisation by our group.21
Surprisingly, we found that almost all the WM115 cells ex-
pressed CD133 as confirmed by FACS, RT-PCR and immunocy-
tochemistry and they also expressed ABCG2. Thus we
hypothesised that this homogeneous expression of CD133
found in practically 95% of WM115 cells might be the conse-
quence of serial sub-cultivations leading to the rise of se-
lected clones with enhanced stem-ness proprieties. To
ascertain this hypothesis, we performed a detailed analysis
of WM115 cells that they possess several phenotypic and
functional features of stem cells. In particular we found: a)
WM115 cells were able to differentiate into neurogenic cell
lineages. WM115 cells expressed markers of precursors and
mature oligodendrocytes and they are positive for mature
neural markers. They did not express GFAP, a marker typical
of mature astrocytes. Thus, they showed some features of
normal hNSC;6,7 b) WM115 cells can differentiate into mesen-
chymal lineages such as adipogenic cells as we clearly dem-
onstrated by their capacity of incorporating Oil Red and
expressing higher levels of adipsin;29 c) WM115 cells showed
strong similarity to hNSC by their capacity to grow as floating
cell aggregates forming spheres under serum free culture
conditions. In addition to these typical cancer stem cell fea-
tures, WM115 showed angiogenic and lymphoangiogenic
markers consistent with its high tumourigenic capacity
in vivo.
WM115 cell line expresses themain angiogenic factors and
in particular notch 430 while SOX18, a factor transiently ex-
pressed in nascent endothelial cells during embryonic devel-
opment and adult neovascularisation is undetectable.31
Regarding lymphoangiogenic markers, WM115 cells ex-
pressed in particular prox-1 which plays a pivotal role in spec-
ifying lymphatic endothelial cell fate.20 Accordingly, D2-40, an
antigen expressed specifically in mature lymphatic ves-
sels32,33 was absent. The idea that tumour stem/initiating
cells may have the potential to induce angiogenesis and/or
lymphoangiogenesis could represent an important new find-
ing suggesting that, besides the typical stem-ness features,
cancer stem cells may also possess this angiogenic repertoire
in order to recapitulate the original tumour. Whether these
properties can be attributed to a multiple interactive cancer
stem unit or can be involved in cross-talk interaction with
neighbouring host stromal cells remains to be clarified.34
The high expression of CD133 onWM115 was in contrast with
the low expression of this marker in melanoma cells derived
from fresh biopsies. This result thus raises the question if
CD133 may represent a good marker for identification of can-
cer stem cells in a melanoma cell line. However, it was impor-
tant to note that the expression of CD133 was dramatically
reduced in level in fresh melanoma biopsies in the xenograft
tumour. In addition, xenograft tumours also showed a signif-icant down modulation of ABCG2, another important marker
of cancer stem cells.19,20 Thus compared to in vitro, the
expression CD133 and ABCG2 on melanoma cells in vivo be-
haved differently. This observation was confirmed by the re-
sult that cultured melanoma cells derived from xenograft
after only a few passages re-expressed high level of both
CD133 and ABCG2 markers. Therefore, it is tempting to spec-
ulate that with CD133+ and ABCG2+ in some tumours, such as
melanoma, quiescent stem-like cells present in the tumour
mass could be ‘re-activated’ by in vitro conditions becoming
the main cellular population after a few passages or could
be due to expansion of a rare CD133+ cells. A recent report
suggested that WM115 grown as floating cell spheroids were
enriched for the expression of CD20, a typical marker of ma-
ture B lymphocyte, and this was associated with a higher
tumourigenic capacity in vivo.25 Thus we have tested the
expression of CD133 and ABCG2 in both WM115 spheroids
and in adherent WM115 cell cultures. Interestingly, a signifi-
cant down modulation of these markers was observed in
WM115 spheres, suggesting that melanoma cells cultured as
floating cell spheroids may behave, at least for the expression
of CD133 and ABCG2 markers, more similarly in vivo
conditions.
In conclusion, our study showed new important insights
into human melanoma. In particular we have identified
CD133+ and ABCG2+ as potential melanoma stem/initiating
cell markers both in vivo and in vitro. Recently, Lee and col-
leagues raised the problem that cancer cell lines could not
be a good model for studying the cancer stem cell biology of
human cancer.35 Our findings indicate that WM115 xeno-
grafts might be a good model since they showed similar levels
of CD133 and ABCG2 detected in biopsy. Another important
aspect is the evidence that WM115, a melanoma cell line
highly enrichedwith cells expressing these markers, concom-
itantly expressed angiogenic and lymphonangiogenic mark-
ers, could suggest that, at least in melanoma, cancer stem/
initiating cells may possess on their own many features that
are distinctive of more aggressive neoplasma.Conflict of interest statement
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